Form 4: Monopar Therapeutics Executive Acquires Stock Options
SEC Form 4
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports acquisition of stock options.
Summary
- Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, filed a Form 4 on May 24, 2024, reporting a transaction.
- The transaction involved the acquisition of 25,000 stock options with an exercise price of $0.6146 on May 22, 2024.
- These options vest in installments, starting with 6/48ths on November 21, 2024, and then 1/48th per month thereafter.
- The options expire on May 22, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which can be seen as a positive sign of aligning management interests with shareholders, but doesn't provide enough information to be strongly positive.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into insider transactions, allowing investors to monitor the actions of company executives and other key stakeholders.
Stakeholder Impact
- Shareholders may view the acquisition of stock options by the COO as a positive sign, aligning his interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Transaction date: Acquisition of stock options. |
| 05/24/2024 | Date of Form 4 filing. |
| 11/21/2024 | Options vest 6/48ths. |
| 05/22/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.